Clinical Trial Evidence: What UK Weight Loss Data Shows
Wegovy Versus Mounjaro: UK Clinical Evidence Comparison
When evaluating Wegovy versus Mounjaro for weight management, UK patients benefit from robust clinical trial data for both treatments. The STEP programme for Wegovy demonstrated that patients taking semaglutide alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in the landmark STEP 1 trial. Mounjaro's SURMOUNT trials showed impressive results with tirzepatide's dual GIP and GLP-1 receptor agonist mechanism.
However, comparing trial percentages directly isn't clinically meaningful since the studies used different populations, endpoints, and methodologies. What matters for UK patients considering Wegovy versus Mounjaro is that both prescription-only medicines have demonstrated substantial weight management benefits when combined with lifestyle modifications. Both treatments are available through EverydayMeds' clinical assessment process, allowing your prescriber to determine which option aligns with your medical history and weight management goals.
Wegovy Versus Mounjaro: UK Pricing and Value Analysis
Understanding the cost structure for Wegovy versus Mounjaro helps UK patients plan their weight management investment effectively. Wegovy pricing at EverydayMeds starts with the 0.25mg starter dose at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the 2.4mg maintenance dose (£209.99). New customers apply code FIRST40 at checkout to reach these final prices, whilst returning patients use DOSE25.
Our bundle options provide convenience for the Wegovy versus Mounjaro decision-making process. The Intro Duo bundle (0.25mg & 0.5mg) costs £169.99, covering your first two months of treatment. For patients reaching maintenance, the Ultimate Stability Trio provides three 2.4mg pens for £649.99, ensuring consistent supply. These prices reflect EverydayMeds' commitment to transparent, accessible weight management solutions through our GPhC-registered pharmacy services.
STEP Trial Results: Wegovy's Clinical Foundation
The evidence base supporting Wegovy versus Mounjaro comparisons draws from peer-reviewed clinical research, particularly the STEP programme published in respected journals. Wilding et al., NEJM, 2021, reported that participants in STEP 1 achieved approximately 15% average weight loss at 68 weeks when taking semaglutide alongside diet and exercise. STEP 3 showed around clinically studied weight loss when combined with intensive behavioural therapy.
Importantly, STEP 5 demonstrated sustained results, with participants maintaining approximately clinically studied weight loss at two years. The recent SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events, adding another dimension to the Wegovy versus Mounjaro consideration for patients with existing cardiovascular risk factors.
How Wegovy Works: GLP-1 Mechanism Explained
Understanding the mechanism behind Wegovy versus Mounjaro helps patients appreciate how each treatment supports weight management differently. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone, glucagon-like peptide-1. This hormone targets brain appetite centres, potentially reducing food cravings and promoting satiety after smaller meals. The once-weekly injection helps maintain consistent hormone levels, supporting appetite regulation throughout your weight management journey. When combined with a reduced-calorie diet and increased physical activity, this mechanism can effectively support long-term weight management goals.
EverydayMeds Ordering Process: From Assessment to Delivery
The pathway to accessing either option in the Wegovy versus Mounjaro comparison begins with EverydayMeds' streamlined clinical assessment process. Our 3-minute online questionnaire captures essential medical history, current medications, and weight management goals to inform prescriber decision-making. Your assessment typically receives prescriber review within 3 working days, with express 24-hour review available for urgent requests. Once approved, your prescription-only medicine ships via next-day delivery using cold-chain, temperature-controlled logistics to maintain medication integrity. Our GPhC-registered pharmacy (#9012878) ensures all treatments meet UK pharmaceutical standards throughout the supply chain.
Storage and Practical Considerations: Wegovy Versus Mounjaro
Practical storage requirements often influence the Wegovy versus Mounjaro decision for UK patients with active lifestyles. Wegovy requires refrigeration at 2-8°C before first use but offers superior travel convenience with 6 weeks room temperature storage below 30°C once removed from the fridge. This compares favourably to Mounjaro's 21-day room temperature limit, making Wegovy potentially more suitable for extended travel or flexible storage needs. The FlexTouch pen system provides intuitive injection experience with clear dose escalation from 0.25mg through to 2.4mg maintenance dosing. Proper dose escalation prevents gastrointestinal side effects whilst allowing your body to adjust gradually to the medication.
UK Patient Outcomes: Real-World Wegovy Versus Mounjaro Experience
Beyond clinical trials, UK patients considering Wegovy versus Mounjaro benefit from post-marketing surveillance data and real-world evidence studies. The STEP programme's diverse population included patients with various BMI ranges and comorbidities, providing relevant data for UK patient demographics. Weight regain studies show that patients typically regained approximately two-thirds of lost weight within one year of stopping treatment, emphasising that weight management represents a long-term commitment rather than a short-term intervention.
Both treatments in the Wegovy versus Mounjaro comparison require ongoing lifestyle modifications, including sustainable dietary changes and regular physical activity. EverydayMeds patients report that the appetite-suppressing effects help maintain these lifestyle changes more effectively, though individual responses vary based on baseline health, adherence, and concurrent lifestyle modifications.
Making Your Choice: Wegovy Versus Mounjaro Clinical Decision
The final decision in any Wegovy versus Mounjaro comparison rests with clinical assessment rather than personal preference alone. Your prescriber considers factors including medical history, current medications, lifestyle requirements, and specific weight management goals when recommending treatment options. Some patients may suit Wegovy's established GLP-1 mechanism, whilst others might benefit from Mounjaro's dual GIP and GLP-1 approach, though both require careful clinical evaluation. EverydayMeds' assessment process captures these nuances, ensuring your treatment recommendation aligns with clinical best practice and NICE guidance. Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which option offers the most appropriate therapeutic approach for your individual circumstances. Start your clinical assessment today using discount codes FIRST40 for new customers or DOSE25 for returning patients, with confidence in our GPhC-registered clinical team's expertise.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
